JPRN-C000000414已完成未知
Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable. - Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have: uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study.
研究者
相似试验
已完成
1 期
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapyJPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18
尚未招募
1 期
Gastric cancer immunotherapyIRCT20170208032451N1Mashhad University of Medical Sciences5
已完成
不适用
Phase I study of immuno-Cell therapy for advanced and recurrent esophageal squamous cell carcinomaAdvanced and recurrent esophageal squamous cell carcinomaJPRN-UMIN000007841Toho University5
进行中（未招募）
2 期
A CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PT 107 (VACCINE) IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTSCTRI/2010/091/001348PIQUE THERAPEUTICS INC100
进行中（未招募）
1 期
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract.The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component.MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2020-001028-32-FRCHU DE NIMES99